(VIANEWS) – The NASDAQ opens in less than hour and Viking Therapeutics‘s pre-market value is already 14.54% up.
Viking Therapeutics’s last close was $69.19, 30.4% under its 52-week high of $99.41.
The last session, NASDAQ finished with Viking Therapeutics (VKTX) dropping 0.52% to $69.19. NASDAQ slid 0.27% to $16,384.47, following the last session’s downward trend on what was a somewhat bearish trend exchanging session.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.79%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 12% and a negative 47.4%, respectively.
More news about Viking Therapeutics (VKTX).
